Abstract: A page content processing method, apparatus and device, and a readable medium are provided. The method comprises: in response to a connection operation of a target content block in a current page, determining a connection content block of the target content block; and at an associated location of one of the target content block and the connection content block, displaying a connection identifier of the other content block, so as to view the other content block by using the connection identifier. Also provided are a document synchronization method, apparatus and device, a medium, a tree structure-based document processing method, apparatus and device, and a medium.

Abstract: The present disclosure relates to a performance testing device applicable to a metal fuel cell, and belongs to the field of metal fuel cells. Self-adaptive clamping equipment can be used for autonomously positioning and clamping galvanic piles with different sizes and shapes, and can be self-adaptively fixed according to the shapes. Sealing performance testing equipment is used for testing the sealing performance of the metal fuel cell through a testing pool. Discharge performance testing equipment is used for testing the discharge performance of the metal fuel cell. According to the performance testing device, two performances of sealing and discharging can be tested at the same time, perfusion of different electrolytes and measurement of galvanic piles composed of different numbers of single cells with different sizes can be realized, and the compatibility requirement of large-batch and multi-type cells delivered from a factory is met.

Abstract: A method for synchronous production of manganese tetraoxide and ferric oxide for a soft magnetic material by using marine polymetallic nodules includes: 1) crushing and grinding marine manganese nodules and baking to a constant weight; thoroughly mixing with a mixed flux and roasting in a muffle furnace; 2) carrying out solid-liquid separation, washing solid-phase precipitates with water, grinding the solid, adding sulfuric acid, controlling the temperature to be below 50° C., and vacuuming a reactor up; 3) adding a reducing agent to react at room temperature for 5-10 min, adding ammonia water to adjust the pH value to 5.5, and carrying out separation and filtering; 4) controlling the temperatures of manganese sulfate and ferric sulfate solutions to be below 50° C., and adding ammonium sulfide; and 5) washing with deionized water, and calcining at 800-900° C. for 1-3 s by a suspension low-temperature instantaneous firing system.

Abstract: Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds thereof, and use of these compounds in preparing drugs for inhibiting ROCK.

Abstract: Provided are certain BTK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Provided are certain RET inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof are provided. In particular, Bcl-2 inhibitors of formula (I) are provided, wherein the variable groups are as defined in the specification. The Bcl-2 inhibitors can be used to treat cell proliferative disorders.

Abstract: Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds thereof, and use of these compounds in preparing drugs for inhibiting ROCK.

Abstract: Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

Abstract: Techniques for neural network training are provided. One computer-implemented method comprises: obtaining, by an electronic device operatively coupled to a processing unit, based on a similarity between two images, a first image and a second image. The computer-implemented method also comprises training, by the electronic device, a neural network based on the first image and the second image such that a distance between a first vector and a second vector generated respectively from the first image and the second image in the trained neural network is associated with the similarity.

Abstract: Techniques for model based data processing are proposed. In one example, a computer-implemented method is as follows. A first model is determined from a first category of data processing models and a second model is determined from a second category of data processing models. The second category can be different from the first category in some instances. Performance of a first combined model of the first and second models can be compared with performance of the first model. A target model for processing data can be selected from the first combined model and the first model based on the comparing.

Abstract: Provided are certain compounds or pharmaceutically acceptable salts thereof which can inhibit kinase activity of Bruton's tyrosine kinase (BTK) and may be useful for the treatment of diseases like cancer, immunological disease and inflammation.

Abstract: Pharmacological compositions comprising a cationic nonribosomal peptide (CNRP) or a salt thereof are described. Further, methods of treating a bacterial infection in a subject by administering to the subject a CNRP or a salt thereof are provided.

Abstract: Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

Abstract: Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof are provided. In particular, Bcl-2 inhibitors of formula (I) are provided, wherein the variable groups are as defined in the specification. The Bc1-2 inhibitors can be used to treat cell proliferative disorders.

Abstract: Certain embodiments of the invention pertain to pharmaceutical compositions comprising a cationic nonribosomal peptide (CNRP) or a salt thereof. Certain other embodiments of the invention pertain to methods of treating a bacterial infection in a subject by administering to the subject a CNRP or a salt thereof.